A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä
A systematic review and meta-analysis of lung cancer risk prediction models
Tekijät: Khalife, Ghida; Nilsson, Matilda; Peltola, Lotta; Waris, Juho; Jekunen, Antti; Leskelä, Riikka-Leena; Andersén, Heidi; Nuutinen, Mikko; Heikkilä, Eija; Nurmi-Rantala, Susanna; Torkki, Paulus
Kustantaja: Informa UK Limited
Julkaisuvuosi: 2025
Journal: Acta Oncologica
Tietokannassa oleva lehden nimi: Acta Oncologica
Vuosikerta: 64
Aloitussivu: 661
Lopetussivu: 671
eISSN: 1651-226X
DOI: https://doi.org/10.2340/1651-226X.2025.42529
Verkko-osoite: https://doi.org/10.2340/1651-226x.2025.42529
Rinnakkaistallenteen osoite: https://research.utu.fi/converis/portal/detail/Publication/498636977
Background: Lung cancer (LC) remains the leading cause of cancer-related mortality worldwide. Early detection through targeted screening significantly improves patient outcomes. However, identifying high-risk individuals remains a critical challenge.
Purpose: This systematic review evaluates externally validated LC risk prediction models to assess their performance and potential applicability in screening strategies.
Methods: Of the 11,805 initial studies, 66 met inclusion criteria and 38 published mainly between 2020 and 2024 were included in the final analysis. Model methodologies, validation approaches, and performance metrics were extracted and compared.
Results: The review identified 18 models utilising conventional machine learning, six employing neural networks, and 14 comparing different predictive frameworks. The Prostate Lung Colorectal and Ovarian Cancer Screening Trial (PLCOm2012) demonstrated superior sensitivity across diverse populations, while newer models, such as Optimized Early Warning model for Lung cancer risk (OWL) and CanPredict, showed promising results. However, differences in population demographics and healthcare systems may limit the generalisability of these models.
Interpretation: While LC risk prediction models have advanced, their applicability to specific healthcare systems, such as Finland's, requires further adaptation and validation. Future research should focus on optimising these models for local contexts to improve clinical impact and cost-effectiveness in targeted screening programmes.
Systematic review registration: PROSPERO CRD42022321391.
Ladattava julkaisu This is an electronic reprint of the original article. |
Julkaisussa olevat rahoitustiedot:
This work was supported by AstraZeneca Finland and MSD Finland. Open access funded by Helsinki University Library.